The downturn in digital health funding – with fewer and smaller deals and a diminished number of backers – could make 2023 the smallest year for financing since 2019, unle
After a bumper 2021, the fall-off in digital health financing deals that started to appear early this year has continued, with the three month to end of September the lowest funded quarter
The buoyant financing environment for digital health companies that took off during the pandemic looks like it has come to an end, according to new figures from market watcher Rock Health.<
For many years, those inside the pharma industry have been telling the same old story about innovation: pharma is big, slow, and risk averse. Start-ups move fast and break things.
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS